ClinicalTrials.gg
CompletedNCT01513473BEGIN™Updated Jun 13, 2019Results posted

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

A Phase 3 interventional study of insulin degludec and insulin detemir in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 81 sites in 12 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2019-06-13.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin degludec · Diabetes Mellitus, Type 1.

Enrollment
5th of 39
350 · median 38
Started
2012
with 3 others
Phase 3
7 of 39
none open now
Registered
18th of 39
by date
Lead sponsor
30 of 39
Novo Nordisk A/S

Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, this one is the 5th largest by enrollment, is one of 4 that started in 2012, is one of 7 in phase 3, and was the 18th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This trial is conducted in Africa, Asia, Europe and the United States of America (USA).

The aim of this trial is to investigate the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 350 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , and child assent as age-appropriate, obtained before any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the subject). The parents or legal representative of the child must sign and date the Informed Consent Form according to local requirements. The child, if possible, parents or legal representative of the child must sign and date the Child Assent Form according to local requirements
  • Male or female diagnosed with type 1 diabetes mellitus (T1DM) (based on clinical judgement and supported by laboratory analysis as per local guidelines)
  • Ongoing daily treatment with insulin (any regimen) for at least 3 months prior to Visit 1 (screening). No OADs (oral anti-diabetic drugs) are allowed
  • (glycosylated ) maximum 11%

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to trial product(s) or related products
  • Previous participation in this trial. Participation is defined as randomisation
  • Girls who are pregnant, breastfeeding or intend to become pregnant
  • Girls who have had menarche and are not using adequate measures according to local requirements
  • Known hypoglycaemic unawareness or recurrent severe hypoglycaemic events as judged by the Investigator (trial physician)
  • More than 1 diabetic ketoacidosis requiring hospitalisation within the last 3 months prior to Visit 1
  • Significant concomitant disease, except for conditions associated with type 1 diabetes mellitus, which in the Investigator's opinion could interfere with the trial
  • The receipt of any drug within 1 month prior to Visit 1
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    Insulin Degludec + Insulin Aspart

    Drug: insulin degludec · Drug: insulin aspart

  • Experimental
    Insulin Detemir +Insulin Aspart

    Drug: insulin detemir · Drug: insulin aspart

Interventions

  • Injected subcutaneously (under the skin) once daily. Dose individually adjusted.

  • Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.

  • Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory)

    Change from baseline in HbA1c (%) after 26 weeks of treatment.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in HbA1c (%) at 52 Weeks (Analysed by Central Laboratory)

    Change from baseline in HbA1c (%) after 52 weeks of treatments.

    Time frame: Week 0, week 52

  2. Change From Baseline in Fasting Blood Glucose (FPG) at 26 Weeks (Analysed by Central Laboratory)

    Change from baseline in FPG after 26 weeks of treatment.

    Time frame: Week 0, week 26

  3. Change From Baseline in Fasting Blood Glucose (FPG) at 52 Weeks (Analysed by Central Laboratory)

    Change from baseline in FPG after 52 weeks of treatment.

    Time frame: Week 0, week 52

  4. Number of Treatment Emergent Adverse Events (TEAEs)

    TEAE is defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

    Time frame: After 26 weeks and 52 weeks of treatment

  5. Number of Hypoglycaemic Episodes

    Number of hypoglycaemic episodes (severe episodes or episodes with plasma glucose (PG) below or equal to 3.9 mmol/L (70 mg/dL) with or without symptoms of hypoglycaemia) during the trial; nocturnal \[11 p.m. - 7 a.m./23:00 - 07:00\] and over the entire day (24 hours)

    Time frame: After 26 weeks and 52 weeks of treatment

  6. Number of Self-measured Hyperglycaemia (Episodes of PG Above 11.1 mmol/L (200 mg/dL))

    Episodes of PG \>11.1mmol/L (200mg/dL)

    Time frame: After 26 weeks and 52 weeks of treatment

  7. Number of Episodes With Self Monitored Blood Ketones Above 1.5 mmol (Capillary Blood Ketone Measurement to be Performed if Self-measured Plasma Glucose (SMPG) Exceeds 14.0 mmol/l (250 mg/dL))

    Blood ketones \> 1.5mmol/L (Capillary blood ketone measurement to be performed if SMPG exceeds 14.0mmol/L (250mg/dL) )after 26 and 52 weeks of treatment

    Time frame: After 26 weeks and 52 weeks of treatment

  8. Steady-state Plasma Concentrations of Insulin Degludec and Insulin Detemir on Three Different Visits (Three Different Weeks) During the First 26 Weeks of Treatment

    Steady state plasma concentrations of insulin degludec and insulin detemir on three different visits (three different weeks) during the trial.

    Time frame: Between week 1 and week 26

  9. Insulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)

    Antibody measurements : the values presented are week 52 (LOCF). The measurement of insulin antibodies after 26 and 52 weeks of treatment was done to fulfil the requirement of monitoring the long term immunogenicity. The unit of measure is percentage bound/total (%B/T) for these antibodies. The Antibodies cross reacting to Human Insulin is abbreviated as X-reacting AB Hu Insulin below)

    Time frame: After 52 weeks of treatment

08

Results

Posted Jan 12, 2016

Participant flow

The trial was conducted at 72 sites in 12 countries as follows: Bulgaria (2), Finland (5), France (4), Germany (3), Italy (2), Japan (15), Netherlands (5), Republic of Macedonia (2), Russian Federation (6), South Africa (2), United Kingdom (4), United States (22)

Main Trial (26 Weeks)
Participant flow — Main Trial (26 Weeks)
MilestoneIDeg + IAspIDet + IAsp
Started174176
Exposed174175
Completed170165
Not completed411
Withdrew: Adverse event02
Withdrew: Withdrawal by subject47
Withdrew: Unclassified02
Extension Trial (26 Weeks)
Participant flow — Extension Trial (26 Weeks)
MilestoneIDeg + IAspIDet + IAsp
Started152128
Completed151122
Not completed16
Withdrew: Adverse event01
Withdrew: Withdrawal by subject15

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory)

Change from baseline in HbA1c (%) after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory)
percentage of glycosylated haemoglobinIDeg + IAspIDet + IAsp
Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory)-0.20 ± 0.95-0.31 ± 0.89
SecondaryChange From Baseline in HbA1c (%) at 52 Weeks (Analysed by Central Laboratory)

Change from baseline in HbA1c (%) after 52 weeks of treatments.

Time frame:
Week 0, week 52
Reported as:
Mean · percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (%) at 52 Weeks (Analysed by Central Laboratory)
percentage of glycosylated haemoglobinIDeg + IAspIDet + IAsp
Change From Baseline in HbA1c (%) at 52 Weeks (Analysed by Central Laboratory)-0.27 ± 1.07-0.22 ± 1.03
SecondaryChange From Baseline in Fasting Blood Glucose (FPG) at 26 Weeks (Analysed by Central Laboratory)

Change from baseline in FPG after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Blood Glucose (FPG) at 26 Weeks (Analysed by Central Laboratory)
mmol/LIDeg + IAspIDet + IAsp
Change From Baseline in Fasting Blood Glucose (FPG) at 26 Weeks (Analysed by Central Laboratory)-0.67 ± 5.990.50 ± 8.37
SecondaryChange From Baseline in Fasting Blood Glucose (FPG) at 52 Weeks (Analysed by Central Laboratory)

Change from baseline in FPG after 52 weeks of treatment.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Blood Glucose (FPG) at 52 Weeks (Analysed by Central Laboratory)
mmol/LIDeg + IAspIDet + IAsp
Change From Baseline in Fasting Blood Glucose (FPG) at 52 Weeks (Analysed by Central Laboratory)-1.29 ± 6.531.10 ± 8.24
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

TEAE is defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

Time frame:
After 26 weeks and 52 weeks of treatment
Reported as:
Number · events
Number of Treatment Emergent Adverse Events (TEAEs)
eventsIDeg + IAspIDet + IAsp
TEAEs -26 weeks810761
TEAEs -52 weeks14621266
SecondaryNumber of Hypoglycaemic Episodes

Number of hypoglycaemic episodes (severe episodes or episodes with plasma glucose (PG) below or equal to 3.9 mmol/L (70 mg/dL) with or without symptoms of hypoglycaemia) during the trial; nocturnal \[11 p.m. - 7 a.m./23:00 - 07:00\] and over the entire day (24 hours)

Time frame:
After 26 weeks and 52 weeks of treatment
Reported as:
Number · episodes
Number of Hypoglycaemic Episodes
episodesIDeg + IAspIDet + IAsp
26 weeks (entire day)1171210991
26 weeks (nocturnal)12611458
52 weeks (entire day)2156018373
52 weeks (nocturnal)23362586
SecondaryNumber of Self-measured Hyperglycaemia (Episodes of PG Above 11.1 mmol/L (200 mg/dL))

Episodes of PG \>11.1mmol/L (200mg/dL)

Time frame:
After 26 weeks and 52 weeks of treatment
Reported as:
Number · episodes
Number of Self-measured Hyperglycaemia (Episodes of PG Above 11.1 mmol/L (200 mg/dL))
episodesIDeg + IAspIDet + IAsp
26 weeks3126431173
52 weeks5867952831
SecondaryNumber of Episodes With Self Monitored Blood Ketones Above 1.5 mmol (Capillary Blood Ketone Measurement to be Performed if Self-measured Plasma Glucose (SMPG) Exceeds 14.0 mmol/l (250 mg/dL))

Blood ketones \> 1.5mmol/L (Capillary blood ketone measurement to be performed if SMPG exceeds 14.0mmol/L (250mg/dL) )after 26 and 52 weeks of treatment

Time frame:
After 26 weeks and 52 weeks of treatment
Reported as:
Number · episodes
Number of Episodes With Self Monitored Blood Ketones Above 1.5 mmol (Capillary Blood Ketone Measurement to be Performed if Self-measured Plasma Glucose (SMPG) Exceeds 14.0 mmol/l (250 mg/dL))
episodesIDeg + IAspIDet + IAsp
26 weeks4486
52 weeks109161
SecondarySteady-state Plasma Concentrations of Insulin Degludec and Insulin Detemir on Three Different Visits (Three Different Weeks) During the First 26 Weeks of Treatment

Steady state plasma concentrations of insulin degludec and insulin detemir on three different visits (three different weeks) during the trial.

Time frame:
Between week 1 and week 26
Reported as:
Mean · pmol/L
Steady-state Plasma Concentrations of Insulin Degludec and Insulin Detemir on Three Different Visits (Three Different Weeks) During the First 26 Weeks of Treatment
pmol/LIDeg + IAspIDet + IAsp
week 24540.4 ± 3999.03972.2 ± 6721.8
week 124148.1 ± 3726.95430.1 ± 9067.7
week 264105.6 ± 3456.56377.0 ± 10930.6
SecondaryInsulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)

Antibody measurements : the values presented are week 52 (LOCF). The measurement of insulin antibodies after 26 and 52 weeks of treatment was done to fulfil the requirement of monitoring the long term immunogenicity. The unit of measure is percentage bound/total (%B/T) for these antibodies. The Antibodies cross reacting to Human Insulin is abbreviated as X-reacting AB Hu Insulin below)

Time frame:
After 52 weeks of treatment
Reported as:
Mean · %B/T
Insulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)
%B/TIDeg + IAspIDet + IAsp
Insulin aspart specific antibodies1.1 ± 2.61.5 ± 2.3
Insulin Detemir specific antibodiesNA ± NA6.1 ± 6.5
Insulin Degludec specific antibodies0 ± 0.3NA ± NA
X-reacting AB Hu Insulin17.2 ± 7.726.0 ± 19.3

Adverse events

Collected over Treatment emergent events (after first trial product administration and no later than 7 days after last trial product administration). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg + IAsp—18/174 (10.3%)146/174 (83.9%)
IDet + IAsp—16/175 (9.1%)143/175 (81.7%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventIDeg + IAspIDet + IAsp
HypoglycaemiaMetabolism and nutrition disorders5/1742/175
Hypoglycaemic seizureNervous system disorders1/1743/175
AppendicitisInfections and infestations1/1742/175
GastroenteritisInfections and infestations1/1742/175
Gastroenteritis viralInfections and infestations0/1742/175
Blood ketone body increasedInvestigations1/1742/175
FaecalomaGastrointestinal disorders1/1740/175
BronchitisInfections and infestations1/1740/175
Respiratory tract infection viralInfections and infestations1/1740/175
Urinary tract infectionInfections and infestations1/1740/175
Most frequent other events
Showing 10 of 25
Most frequent other events
EventIDeg + IAspIDet + IAsp
NasopharyngitisInfections and infestations72/17467/175
HeadacheNervous system disorders46/17451/175
Blood ketone body increasedInvestigations31/17446/175
Upper respiratory tract infectionInfections and infestations34/17424/175
Oropharyngeal painRespiratory, thoracic and mediastinal disorders29/17434/175
CoughRespiratory, thoracic and mediastinal disorders31/17428/175
PyrexiaGeneral disorders30/17428/175
Abdominal pain upperGastrointestinal disorders28/17417/175
VomitingGastrointestinal disorders26/17422/175
HypoglycaemiaMetabolism and nutrition disorders26/17417/175

Baseline characteristics

Full Analysis set (FAS) included all randomised subjects.

Age, Categorical
Age, Categorical(Participants)IDeg + IAspIDet + IAspTotal
<=18 years174176350
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)IDeg + IAspIDet + IAspTotal
Female7878156
Male9698194
09

Study locations

81 sites
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72202, United States
  • Novo Nordisk Investigational Site
    Orange, California 92868, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92123, United States
  • Novo Nordisk Investigational Site
    Aurora, Colorado 80045, United States
  • Novo Nordisk Investigational Site
    New Haven, Connecticut 06511, United States
  • Novo Nordisk Investigational Site
    Gainesville, Florida 32608, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32207, United States
  • Novo Nordisk Investigational Site
    Maitland, Florida 32751, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32901, United States
  • Novo Nordisk Investigational Site
    Tallahassee, Florida 32308, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30322, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30339, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40202, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21201, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21229, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02215, United States
  • Novo Nordisk Investigational Site
    Worcester, Massachusetts 01655, United States
  • Novo Nordisk Investigational Site
    Buffalo, New York 14203, United States
  • Novo Nordisk Investigational Site
    Akron, Ohio 44308, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45229, United States
  • Novo Nordisk Investigational Site
    Hershey, Pennsylvania 17033, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75235, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78207, United States
  • Novo Nordisk Investigational Site
    Norfolk, Virginia 23507, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23235, United States
  • Novo Nordisk Investigational Site
    Sofia, 1606, Bulgaria
  • Novo Nordisk Investigational Site
    Varna, 9010, Bulgaria
  • Novo Nordisk Investigational Site
    Espoo, 02740, Finland
  • Novo Nordisk Investigational Site
    Kuopio, 70210, Finland
  • Novo Nordisk Investigational Site
    Mikkeli, 50100, Finland
  • Novo Nordisk Investigational Site
    OYS, 90029, Finland
  • Novo Nordisk Investigational Site
    Pori, 28500, Finland
  • Novo Nordisk Investigational Site
    BRON cedex, 69677, France
  • Novo Nordisk Investigational Site
    Paris, 75015, France
  • Novo Nordisk Investigational Site
    Rennes, 35056, France
  • Novo Nordisk Investigational Site
    Toulouse, 31059, France
  • Novo Nordisk Investigational Site
    Berlin, 13353, Germany
  • Novo Nordisk Investigational Site
    Hannover, 30173, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    Münster, 48155, Germany
  • Novo Nordisk Investigational Site
    Chieti, 66100, Italy
  • Novo Nordisk Investigational Site
    Genova, 16147, Italy
  • Novo Nordisk Investigational Site
    Roma, 00165, Italy
  • Novo Nordisk Investigational Site
    Chuo-shi, Yamanashi, 409 3898, Japan
  • Novo Nordisk Investigational Site
    Fukushima, 963-8851, Japan
  • Novo Nordisk Investigational Site
    Iruma-gun, Saitama, 350 0495, Japan
  • Novo Nordisk Investigational Site
    Kobe-shi, Hyogo, 657-0846, Japan
  • Novo Nordisk Investigational Site
    Kochi-shi, Kochi, 780 0952, Japan
  • Novo Nordisk Investigational Site
    Kumamoto-shi, Kumamoto, 860 8556, Japan
  • Novo Nordisk Investigational Site
    Maebashi-shi, Gunma, 371-8511, Japan
  • Novo Nordisk Investigational Site
    Musashino-shi, Tokyo, 180 0023, Japan
  • Novo Nordisk Investigational Site
    Niigata-shi, Niigata, 951 8520, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 545 8586, Japan
  • Novo Nordisk Investigational Site
    Sendai-shi, Miyagi, 980 8574, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 157 8535, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 162 8666, Japan
  • Novo Nordisk Investigational Site
    Toyonaka-city, Osaka, 560 0004, Japan
  • Novo Nordisk Investigational Site
    Tsu-shi, Mie, 514 0125, Japan
  • Novo Nordisk Investigational Site
    Almere, 1315 RA, Netherlands
  • Novo Nordisk Investigational Site
    Amersfoort, 3816 CP, Netherlands
  • Novo Nordisk Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • Novo Nordisk Investigational Site
    Nijmegen, 6532 CL, Netherlands
  • Novo Nordisk Investigational Site
    Rotterdam, 3011 TA, Netherlands
  • Novo Nordisk Investigational Site
    Skopje, 1000, North Macedonia
  • Novo Nordisk Investigational Site
    Moscow, 117036, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 119049, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 125373, Russian Federation
  • Novo Nordisk Investigational Site
    Novosibirsk, 630048, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 191144, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410028, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410054, Russian Federation
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 2193, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, Western Cape 7925, South Africa
  • Novo Nordisk Investigational Site
    Aberdeen, AB25 2ZG, United Kingdom
  • Novo Nordisk Investigational Site
    Birmingham, B4 6NH, United Kingdom
  • Novo Nordisk Investigational Site
    Manchester, M13 9WL, United Kingdom
  • Novo Nordisk Investigational Site
    Norwich, NR4 7UY, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S102TH, United Kingdom
10

References and documents

Publications

  • Thalange N, Deeb L, Klingensmith G, Franco DR, Bardtrum L, Tutkunkardas D, Danne T. The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials. Pediatr Diabetes. 2019 May;20(3):314-320. doi: 10.1111/pedi.12821. Epub 2019 Feb 10. PubMed 30666772 ↗
  • Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A, Silverstein J, Tumini S, Ocampo Francisco AM, Kinduryte O, Danne T. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2015 May;16(3):164-76. doi: 10.1111/pedi.12263. Epub 2015 Feb 12. PubMed 25683037 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Jul 2013, 18 months.

Results were first posted in Jan 2016, 2 years 5 months after primary completion. A results delay was requested in Nov 2013.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 18 months is close to that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2012
First posted
Jan 20, 2012
StartActual
Jan 16, 2012
Primary completionActual
Jul 30, 2013
CompletionActual
Jul 30, 2013
Results delay requested
Nov 7, 2013
Results first posted
Jan 12, 2016
Last update
Jun 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01513473
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Jan 16, 2012
Primary completion
Jul 30, 2013
Completion
Jul 30, 2013
Results posted
Jan 12, 2016
Last update
Jun 13, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Detemir

Start the discussion